12.50
price up icon4.17%   0.50
after-market After Hours: 12.25 -0.25 -2.00%
loading
Ocular Therapeutix Inc stock is traded at $12.50, with a volume of 2.97M. It is up +4.17% in the last 24 hours and up +29.94% over the past month. Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
See More
Previous Close:
$12.00
Open:
$12
24h Volume:
2.97M
Relative Volume:
1.30
Market Cap:
$1.99B
Revenue:
$61.10M
Net Income/Loss:
$-138.36M
P/E Ratio:
-9.2593
EPS:
-1.35
Net Cash Flow:
$-90.59M
1W Performance:
+7.20%
1M Performance:
+29.94%
6M Performance:
+63.61%
1Y Performance:
+58.43%
1-Day Range:
Value
$11.57
$12.53
1-Week Range:
Value
$10.58
$12.53
52-Week Range:
Value
$5.80
$12.53

Ocular Therapeutix Inc Stock (OCUL) Company Profile

Name
Name
Ocular Therapeutix Inc
Name
Phone
781-357-4000
Name
Address
15 CROSBY DRIVE, BEDFORD, MA
Name
Employee
274
Name
Twitter
@OCUTX
Name
Next Earnings Date
2025-03-03
Name
Latest SEC Filings
Name
OCUL's Discussions on Twitter

Compare OCUL with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
OCUL
Ocular Therapeutix Inc
12.50 1.91B 61.10M -138.36M -90.59M -1.35
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
385.65 96.11B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
555.13 60.40B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
428.14 54.91B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
673.15 41.30B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
298.52 33.25B 3.81B -644.79M -669.77M -6.24

Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-08-25 Initiated William Blair Outperform
Mar-18-25 Initiated RBC Capital Mkts Outperform
Mar-11-25 Initiated Needham Buy
Oct-16-24 Initiated Scotiabank Sector Outperform
Jun-20-24 Upgrade TD Cowen Hold → Buy
May-31-24 Resumed Piper Sandler Overweight
Feb-09-24 Initiated BofA Securities Buy
Apr-21-23 Initiated Robert W. Baird Outperform
Aug-10-22 Resumed Berenberg Buy
Aug-10-21 Upgrade H.C. Wainwright Neutral → Buy
Dec-28-20 Downgrade H.C. Wainwright Buy → Neutral
Dec-17-20 Initiated Berenberg Buy
Nov-13-20 Reiterated Raymond James Strong Buy
Aug-10-20 Reiterated H.C. Wainwright Buy
Mar-03-20 Upgrade Raymond James Outperform → Strong Buy
May-21-19 Downgrade Cowen Outperform → Market Perform
May-21-19 Reiterated H.C. Wainwright Buy
May-21-19 Downgrade Raymond James Strong Buy → Outperform
Dec-03-18 Reiterated Cantor Fitzgerald Overweight
Nov-15-18 Initiated Raymond James Strong Buy
Sep-07-18 Initiated Piper Jaffray Overweight
Oct-24-17 Initiated Guggenheim Buy
Jul-26-17 Initiated H.C. Wainwright Buy
Jul-12-17 Reiterated Cantor Fitzgerald Overweight
Jun-23-17 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-10-17 Initiated Cantor Fitzgerald Overweight
Nov-15-16 Reiterated RBC Capital Mkts Outperform
Aug-11-16 Initiated JMP Securities Mkt Outperform
Feb-17-16 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15 Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-13-15 Initiated Morgan Stanley Overweight
View All

Ocular Therapeutix Inc Stock (OCUL) Latest News

pulisher
01:20 AM

Ocular Therapeutix stock hits 52-week high at 12.38 USD - Investing.com

01:20 AM
pulisher
08:42 AM

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q2 2025 Earnings Call Transcript - Insider Monkey

08:42 AM
pulisher
06:56 AM

Ocular Therapeutix: Q2 Earnings Snapshot - Huron Daily Tribune

06:56 AM
pulisher
02:25 AM

Ocular Therapeutix Inc (OCUL) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial Strength - GuruFocus

02:25 AM
pulisher
02:24 AM

Ocular Therapeutix Inc (OCUL) Q2 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada

02:24 AM
pulisher
01:47 AM

Ocular Therapeutix 2025 Q2 Earnings Deepening Losses Amid Strategic Momentum - AInvest

01:47 AM
pulisher
01:00 AM

Ocular Therapeutix Reports Second Quarter 2025 Financial Results - VisionMonday.com

01:00 AM
pulisher
12:51 PM

Ocular Therapeutix Reports Q2 2025 Financial Results - TipRanks

12:51 PM
pulisher
12:06 PM

Decoding Ocular Therapeutix Inc (OCUL): A Strategic SWOT Insight - GuruFocus

12:06 PM
pulisher
Aug 05, 2025

OCUL Sales Drop 18% - The Motley Fool

Aug 05, 2025
pulisher
Aug 05, 2025

Ocular Therapeutix Earnings Call: Positive Outlook Amid Trial Progress - TipRanks

Aug 05, 2025
pulisher
Aug 05, 2025

Ocular Therapeutix Q2 2025: Unpacking Key Contradictions in SOL-R Trial Criteria and FDA Relations - AInvest

Aug 05, 2025
pulisher
Aug 05, 2025

Ocular Therapeutix stock maintains Buy rating at TD Cowen ahead of Phase III data - Investing.com Canada

Aug 05, 2025
pulisher
Aug 05, 2025

Ocular Therapeutix Q2 2025 Earnings Call Transcript - MarketBeat

Aug 05, 2025
pulisher
Aug 05, 2025

Clear Street reiterates Buy rating on Ocular Therapeutix stock at $18 - Investing.com Canada

Aug 05, 2025
pulisher
Aug 05, 2025

Raymond James reiterates Strong Buy on Ocular Therapeutix stock with $19 target - Investing.com Canada

Aug 05, 2025
pulisher
Aug 05, 2025

Earnings call transcript: Ocular Therapeutix misses Q2 2025 earnings, stock drops - Investing.com

Aug 05, 2025
pulisher
Aug 05, 2025

Ocular Therapeutix Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 05, 2025
pulisher
Aug 05, 2025

Ocular Therapeutix tumbles as Q2 results miss estimates - Investing.com

Aug 05, 2025
pulisher
Aug 05, 2025

Ocular Therapeutix: Can AXPAXLI's Pipeline Offset Financial Headwinds? - AInvest

Aug 05, 2025
pulisher
Aug 05, 2025

Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance

Aug 05, 2025
pulisher
Aug 05, 2025

Ocular Therapeutix Inc earnings missed by $0.04, revenue fell short of estimates - Investing.com

Aug 05, 2025
pulisher
Aug 05, 2025

Ocular Therapeutix Reports Second Quarter 2025 Financial Results and Business Highlights - TradingView

Aug 05, 2025
pulisher
Aug 05, 2025

Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights - The Manila Times

Aug 05, 2025
pulisher
Aug 05, 2025

OCULAR THERAPEUTIX, INC SEC 10-Q Report - TradingView

Aug 05, 2025
pulisher
Aug 05, 2025

Ocular Therapeutix raises $97mln, expects cash runway into 2028. - AInvest

Aug 05, 2025
pulisher
Aug 04, 2025

What's Next: Ocular Therapeutix's Earnings Preview - 富途牛牛

Aug 04, 2025
pulisher
Aug 04, 2025

Ocular Therapeutix stock maintains Strong Buy rating at Raymond James By Investing.com - Investing.com Canada

Aug 04, 2025
pulisher
Aug 04, 2025

Ocular Therapeutix Inc (OCUL) Q2 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus

Aug 04, 2025
pulisher
Aug 04, 2025

What analysts say about Ocular Therapeutix Inc. stockBuild wealth with high-performing stocks - Jammu Links News

Aug 04, 2025
pulisher
Aug 03, 2025

Is Ocular Therapeutix Inc. a growth stock or a value stockHigh-yield investments - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

When is Ocular Therapeutix Inc. stock expected to show significant growthAchieve impressive returns with smart timing - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are the latest earnings results for Ocular Therapeutix Inc.Capitalize on market shifts with expert advice - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How does Ocular Therapeutix Inc. compare to its industry peersBreakout stock performance - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How does Ocular Therapeutix Inc. generate profit in a changing economyInvest confidently with data-backed picks - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is it the right time to buy Ocular Therapeutix Inc. stockTriple-digit growth rates - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Should I hold or sell Ocular Therapeutix Inc. stock in 2025Capitalize on market trends with expert guidance - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How volatile is Ocular Therapeutix Inc. stock compared to the marketBuild a diversified portfolio for steady profits - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are Ocular Therapeutix Inc. company’s key revenue driversGet daily updates on top-performing stocks - Jammu Links News

Aug 03, 2025
pulisher
Aug 02, 2025

Is Ocular Therapeutix Inc. stock overvalued or undervaluedBuild wealth steadily with smart trading - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

What is Ocular Therapeutix Inc. company’s growth strategyAchieve rapid portfolio appreciation - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

How strong is Ocular Therapeutix Inc. company’s balance sheetExtraordinary performance - Jammu Links News

Aug 02, 2025
pulisher
Jul 31, 2025

Does Ocular Therapeutix Inc. stock perform well during market downturnsLow Risk Guidance That Work - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 31, 2025

Identifying reversal signals in Ocular Therapeutix Inc.Watchlist for Low Risk High Return Stocks Updated - metal.it

Jul 31, 2025
pulisher
Jul 30, 2025

Using data filters to optimize entry into Ocular Therapeutix Inc.Risk Managed Intraday Trade Alerts Increase in Volume - metal.it

Jul 30, 2025
pulisher
Jul 30, 2025

Quantitative breakdown of Ocular Therapeutix Inc. recent moveReliable Alerts for Daily Stock Movers Released - metal.it

Jul 30, 2025
pulisher
Jul 30, 2025

Ocular Therapeutix Inc. Reaches Critical Trendline SupportTrend Analysis for Safer Trades Gains Popularity - metal.it

Jul 30, 2025
pulisher
Jul 29, 2025

Can Ocular Therapeutix Inc. Rally Enough to Break EvenTechnical Entry Strategy for Beginners Explained - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025 - GlobeNewswire

Jul 29, 2025
pulisher
Jul 29, 2025

After Leaping 31% Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Are Not Flying Under The Radar - simplywall.st

Jul 29, 2025
pulisher
Jul 29, 2025

Ocular Therapeutix Sets Q2 Earnings Date: Key Retina Biotech Updates Coming August 5 - Stock Titan

Jul 29, 2025

Ocular Therapeutix Inc Stock (OCUL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.65
price down icon 0.10%
$37.12
price down icon 2.08%
$111.26
price down icon 0.31%
$28.52
price down icon 2.09%
$111.30
price up icon 0.21%
biotechnology ONC
$298.52
price down icon 2.84%
Cap:     |  Volume (24h):